For chronic lymphocytic leukemia (CLL), high BCL-2 and MCL-1 expression levels have been reported to mediate resistance to chlorambucil, fludarabine, and rituximab [7–9]. Here, MCL1 is linked to B-cell chronic lymphocytic leukemia.